Sarmguide is reader-supported. We may earn a commission from partner links. How we earn

SARMs: Every Compound, the Evidence and Our Guides

Every SARM we cover, with its human evidence and key risk at a glance, and every Sarmguide guide by topic: results, side effects, PCT, the law, testing and buying.

SARMs (selective androgen receptor modulators) are experimental drugs that act on the same receptor as testosterone. None is an approved medicine; the best-studied ones added about 1 to 1.5 kg of lean mass in trials while lowering testosterone and HDL cholesterol, and liver injury is the main serious harm seen in real-world use (Adolf 2026). This page lists every SARM we cover with its evidence at a glance, and every Sarmguide guide by topic. For the full explanation, read our complete SARMs guide; if you are new, start here.

Every SARM, at a glance

SARM Human evidence Key finding Key risk
Ostarine (MK-2866) Phase 2 and Phase 3 trials +1.3 kg lean mass vs placebo on 3 mg/day for 86 days (Dalton 2011) HDL fell up to 27%; lower total testosterone
LGD-4033 (ligandrol) Two randomized trials +1.21 kg lean mass on 1 mg/day for 21 days (Basaria 2013) Testosterone, SHBG and HDL fell even at 1 mg
RAD-140 (testolone) One Phase 1 cancer trial Muscle never measured in people (LoRusso 2022) AST rose in 59% of trial patients
Andarine (S4) None Restored muscle and bone in castrated rats (Gao 2005) Human data limited to case and adverse event reports
S-23 None Studied in rats as a male contraceptive (Jones 2009) LH cut by more than half in rats
YK-11 None “Myostatin” effect seen only in mouse muscle cells (Kanno 2013) Stroke linked to an FDA-tested product (FDA)
AC-262 (accadrine) None One 2-week rat study (Piu 2008) Unknown
ACP-105 None Rat and mouse studies (Schlienger 2009) Unknown; toxicity only predicted
RAD-150 (TLB-150) None No published studies (ClinicalTrials.gov) Unknown

Sold next to SARMs but not SARMs: MK-677 (ibutamoren), a growth hormone secretagogue; cardarine (GW501516), a PPAR-delta agonist stopped after cancers in rodent studies (Toxicologist 2009); and SR9009 (stenabolic), a REV-ERB agonist never tested in people. Also covered: LGD-3303, LGD-2226, GW0742 and SR9011.

How far each compound got in clinical research Furthest stage of human clinical trials reached (Preclinical = animal or cell studies only; Approved = approved as a medicine somewhere).
How far each compound got in clinical researchOstarine: Phase 3 (8 human studies); LGD-4033: Phase 2 (2 human studies); RAD-140: Phase 1/2 (1 human study); Andarine (S4): Preclinical (0 human studies); S-23: Preclinical (0 human studies); YK-11: Preclinical (0 human studies); AC-262: Preclinical (0 human studies); ACP-105: Preclinical (0 human studies); RAD-150: Preclinical (0 human studies)PreclinicalPhase 1Phase 2Phase 3ApprovedOstarineOstarine: Phase 3 (8 human studies)Phase 3LGD-4033LGD-4033: Phase 2 (2 human studies)Phase 2RAD-140RAD-140: Phase 1/2 (1 human study)Phase 1/2Andarine (S4)Andarine (S4): Preclinical (0 human studies)PreclinicalS-23S-23: Preclinical (0 human studies)PreclinicalYK-11YK-11: Preclinical (0 human studies)PreclinicalAC-262AC-262: Preclinical (0 human studies)PreclinicalACP-105ACP-105: Preclinical (0 human studies)PreclinicalRAD-150RAD-150: Preclinical (0 human studies)Preclinical

Source: Sarmguide compound database.

Embed this chart

Free to use with the credit link.

Filter and sort every compound, including PCT drugs and peptides, in the SARMs database.

Guides by topic

Basics

Results and goals

Side effects and safety

Hormones, PCT and bloodwork

Law and drug testing

Product forms and buying

Tools

Three things to know before anything else

  1. The evidence is thin. Only ostarine, LGD-4033 and RAD-140 have been tested in human trials, mostly in patients or older adults, for weeks to a few months (Dalton 2011; Basaria 2013; LoRusso 2022). The rest have animal or cell data only.
  2. Products are often not what the label says. Of 44 products sold online as SARMs, only 52% contained a SARM and 41% matched the label amount (Van Wagoner 2017).
  3. They are banned in sport and restricted by law. WADA bans SARMs at all times (WADA 2026); the FDA says they are unapproved drugs, not supplements (FDA); in the UK they cannot be sold as food or supplements (UK Anti-Doping); in Australia possession without a prescription is illegal (Poisons Standard 2026).

Sources

  1. Selective Androgen Receptor Modulators (SARMs) in Sport: Patterns of Use, Product Contamination, Health Risks and Doping-Control Implications 2026 · PMID 42919612
  2. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial 2011 · PMID 22031847
  3. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men 2013 · PMID 22459616
  4. A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer 2022 · PMID 34565686
  5. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats 2005 · PMID 16099859
  6. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception 2009 · PMID 18772237
  7. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression 2013 · PMID 23995658
  8. FDA: Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more (content current as of 2 December 2025) 2025
  9. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator 2008 · PMID 18164613
  10. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators 2009 · PMID 19856921
  11. ClinicalTrials.gov search for 'RAD-150', 'RAD150' and 'TLB-150': no studies found (checked 30 October 2026) 2026
  12. Rat carcinogenicity study with GW501516, a PPAR delta agonist (Geiger et al., The Toxicologist 2009, abstract 895) 2009
  13. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet 2017 · PMID 29183075
  14. WADA: The Prohibited List (2026 List, in force from 1 January 2026) 2026
  15. SARMs | UK Anti-Doping (supplement ingredient warning, updated 29 April 2026) 2026
  16. Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 (F2026L00633) 2026